« All News

Renown Appoints Joseph Grzymski as Chief Science Officer

 

Taking the next step toward expanding its landmark population health and genetics research initiative to a statewide and national level, Renown recently appointed Joseph Grzymski, PhD, a recognized leader in biomedical and translational research, as the organization’s first Chief Scientific Officer (CSO).

An associate research professor of microbiology and computational biology at the Desert Research Institute (DRI), Dr. Grzymski has an extensive background in data analysis, bioinformatics and public health. He serves as senior director of DRI’s Applied Innovation Center and principal investigator of the Healthy Nevada Project – a pioneering population health study launched in 2016 by Renown and DRI. The project which initially enrolled 10,000 volunteers for free genetic testing in less than 48 hours, now has more than 35,000 enrollees, and is on track to include 10 percent of northern Nevada’s population by the end of 2018.

To accelerate innovation at the national level, Dr. Grzymski will work to engage fellow scientists, researchers, physicians and health systems across the U.S. to build new strategic partnerships that will extend the Healthy Nevada Project wellness model to serve additional communities and populations.

“I know of no other health system with such dedication to predicting, preempting and preventing disease and I am truly honored to lead the research and scientific efforts at Renown Health,” said Dr. Grzymski. “We are building a pipeline of healthcare innovation and transformative research with an incredible team assembled by Renown IHI. I look forward to continuing to expand our efforts and rapidly advancing the genomic and health information that is available to improve clinical care in Nevada and across the country and inform people at high risk for disease, so they can seek information and treatment if needed.”

In his role as Renown CSO, Dr. Grzymski will lead the not-for-profit health system’s organizational efforts to advance and expand its portfolio of genetic study participants to evaluate data to better understand the patterns that contribute to population-level health and disease while providing individualized feedback to participants, so they can modify behaviors to reduce risks and improve health.